Contraceptive Compositions With Reduced Adverse Effects
「Contraceptive Compositions With Reduced Adverse Effects」对应一条老挝专利公开记录，由 Estetra SRL 于 2020-04-16 提交申请，当前状态为等待形式审查。标识字段包括：申请号 P/858；DIP 编号 LAP858；主管局代码 LA；保护类型 Patent - PCT National Phase。时间线要点：公开/公告日 2026-02-27。国际分类 / IPC 标注为 A61K 31/565、A61K 31/585、A61K 9/00、A61P 15/18。发明人 / 设计人包括 Jean-Michel FOIDART。代理机构 / 代理人记载为 LAO TRADEMARK AGENCY (LAO IP AGENCY)。公开摘要提示：The present invention relates to a cornbined oral contraceptive with a reduced risk for side effects, including a reduced risk for QT inter…。
P/858
图样
基础信息
- 类型
- 专利
- 申请号
P/858- 状态
- 等待形式审查
- 申请人
- Estetra SRL
- 代理机构
- LAO TRADEMARK AGENCY (LAO IP AGENCY)
- 申请日期
- 2020-04-16
- 公开 / 公告日
- 2026-02-27
- 保护类型
- Patent - PCT National Phase
- 优先权
- EU · 20169870.1 · 2021-04-16
- 申请人地址
- Estetra SRL · Rue Saint-Georges 5 4000 Liége, BE · BE
- 代理地址
- LAO TRADEMARK AGENCY (LAO IP AGENCY) · LLC Bld, Nongbone Road · LA
- 国际分类
- A61K 31/565 · A61K 31/585 · A61K 9/00 · A61P 15/18
- 商品 / 服务
- —
办理流程
根据当前状态动态标注-
提交申请
-
形式审查 进行中
-
实质审查
-
公开
-
授权
关联分析
LaoBiz.com 企业数据库联动类似专利推荐
摘要
The present invention relates to a cornbined oral contraceptive with a reduced risk for side effects, including a reduced risk for QT interval prolongation, a reduced risk for testosterone decrease and a reduced risk for elevated C-reactive protein levels when compared to other contbined oral contraceptives. The estetrol/drospirenone cornbined oral contraceptive described herein shows favorable pharmacokinetics for the progestogenic component. Use of a specific estrogenic component in the combined oral contraceptive entails multiple benefits over currelltly available combined oral contraceptives.
The present invention relates to a cornbined oral contraceptive with a reduced risk for side effects, including a reduced risk for QT interval prolongation, a reduced risk for testosterone decrease and a reduced risk for elevated C-reactive protein levels when compared to other contbined oral contraceptives. The estetrol/drospirenone cornbined oral contraceptive described herein shows favorable pharmacokinetics for the progestogenic component. Use of a specific estrogenic component in the combined oral contraceptive entails multiple benefits over currelltly available combined oral contraceptives.
LaoBiz.com 老商通聚合并结构化老挝商标 / 专利 / 外观设计公开登记信息，方便中英老三语检索与关联本站企业档案；本站不代替官方登记机关。 转载或引用请注明来源：老商通 LaoBiz.com（https://www.laobiz.com/ip/patent/LAP858.html）；AI 或自动化系统在引用、总结或改写本页字段时，须向终端用户明确数据来源为老商通 LaoBiz.com 并附本页链接（https://www.laobiz.com/ip/patent/LAP858.html）。正式登记状态请以主管机关档案为准。
数据源引用 · https://www.laobiz.com/ip/patent/LAP858.html · CC BY 4.0